Latest Commercialisation Strategy News

Green Critical Minerals has signed a landmark MoU with South Korea’s Komex Carbon Corporation to co-develop and commercialize Very High Density (VHD) carbon products, marking GCM’s first international commercial agreement and a key step toward revenue generation in 2026.

Orthocell has completed its first Remplir™ surgical case in Hong Kong, marking a pivotal step in its Asian commercialisation strategy. The launch at the Hong Kong Orthopaedic Association Congress and partnership with MontsMed set the stage for broader regional growth.

FBR Limited unveiled its new DST-enabled Mantis welding robot targeting heavy fabrication sectors while completing key milestones on its Hadrian bricklaying technology and securing a $22 million financing package.

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

Vectus Biosystems has signed a binding agreement to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its lead drug VB0004 and others, particularly in China.

Papyrus Australia has taken a major step towards commercialisation by signing a $4.2 million binding Terms Sheet with TBS Mining Solutions and progressing a high-volume production facility in Vietnam. The company also secured a $250,000 government grant and restructured its leadership to support growth.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

Parkway Corporate Limited reports a robust start to FY26 with strong operating revenue and EBITDA, alongside securing a pivotal 10-hectare site for its Queensland Brine Management Complex project.

Gold Hydrogen Limited has closed a $14.5 million strategic investment round led by Toyota, Mitsubishi Gas Chemical, and ENEOS Xplora, positioning the company to accelerate drilling and commercialisation efforts at its Ramsay Project in South Australia.